Next Post

Drug companies are making an accounting change after the SEC cracked down on Biogen

Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in which they have acquired equity stakes.Related Posts:Brightcom partners with Intent IQ Pfizer Inc. PFE, +1.22%, Merck & Co. MRK, +0.43%, […]